ELU 001
Alternative Names: ELU-001Latest Information Update: 28 Jun 2025
At a glance
- Originator Elucida Oncology
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Folic acids; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Ovarian-cancer(Treatment-resistant) in USA (unspecified route)
- 07 Aug 2024 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05001282)
- 07 Aug 2024 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route) (NCT05001282)